Biopharmaceuticals
HIV/AIDS
News Release - October 1, 2007
Theratechnologies Reports Positive 52-Week Phase 3 Results for its Lead Drug Candidate Tesamorelin
Source: Theratechnologies
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.